Pharsight

1. List of Actonel drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718634	APIL	Method of treatment using bisphosphonic acid	May, 2023 (3 months from now)
US7192938	APIL	Method of treatment using bisphosphonic acid	May, 2023 (3 months from now)
US7718634 (Pediatric)	APIL	Method of treatment using bisphosphonic acid	Nov, 2023 (9 months from now)
US7192938 (Pediatric)	APIL	Method of treatment using bisphosphonic acid	Nov, 2023 (9 months from now)

Market Authorisation Date: 27 March, 1998

Treatment: Treatment of osteoporosis in postmenopausal women; Prevention and treatment of osteoporosis

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg, 30 mg and 35 mg	23 Apr, 2004	1	05 Oct, 2007	10 Jun, 2018	Eligible
75 mg	07 Sep, 2007	1		10 Jun, 2018	Extinguished
150 mg	12 Aug, 2008	1	13 Jun, 2014	06 May, 2023	Extinguished

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription
35MG	TABLET;ORAL	Prescription
75MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
150MG	TABLET;ORAL	Prescription

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246989	APIL	Dosage forms of bisphosphonates	Jan, 2026 (2 years from now)
US7645459	APIL	Dosage forms of bisphosphonates	Jan, 2028 (4 years from now)
US7645460	APIL	Dosage forms of risedronate	Jan, 2028 (4 years from now)

Market Authorisation Date: 08 October, 2010

Treatment: Treatment of osteoporosis in postmenopausal women

Dosage: TABLET, DELAYED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
35 mg	09 Jun, 2011	1	18 May, 2015	09 Jan, 2028	Deferred

Strength	Dosage	Availability
35MG	TABLET, DELAYED RELEASE;ORAL	Prescription

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572779	APIL	Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation	Oct, 2025 (2 years from now)

Market Authorisation Date: 20 August, 2004

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984	APIL	Extended estrogen dosing contraceptive regimen	Feb, 2029 (6 years from now)

Market Authorisation Date: 21 October, 2010

Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/0.01 mg, 0.01 mg and 75 mg	29 Apr, 2011	1		02 Feb, 2029	Extinguished

Strength	Dosage	Availability
0.01MG,0.01MG;1MG,N/A	TABLET;ORAL	Prescription

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984	APIL	Extended estrogen dosing contraceptive regimen	Feb, 2029 (6 years from now)